Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,319 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,657 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07488676 | A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors | recruiting | Phase 1 / Phase 2 | 150 | Astellas Pharma Global Development, Inc.INDUSTRY | 2 | Sep 22, 2026 | clinicaltrials |
| NCT07565740 | Intranasal WSK-IM05 Vaccine Plus Tislelizumab as Neoadjuvant Therapy for HPV+ OPSCC | recruiting | Phase 1 | 9 | West China HospitalOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07570979 | A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer | recruiting | Phase 1 | 208 | Novartis PharmaceuticalsINDUSTRY | 6 | Sep 22, 2026 | clinicaltrials |
| NCT07619521 | Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07661095 | A Study of CRD3874-SI in People With Leukemia | recruiting | Phase 1 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07801508 | A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors | recruiting | Phase 1 | 66 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07824349 | JUR-003 in Adult Patients With Metastatic Prostate Cancer | recruiting | Phase 1 | 210 | Juri Biosciences, Inc.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07830667 | A Phase 1/2 Study of CBX-12 in Children, Adolescents, or Young Adults With Solid Tumors That Have Come Back After Treatment or Are Difficult to Treat | not yet recruiting | Phase 1 / Phase 2 | 79 | Children's Oncology GroupNETWORK | 0 | Sep 22, 2026 | clinicaltrials |
| NCT07835035 | Rimegepant Plus Toripalimab in Advanced Urothelial Carcinoma After Failure of Standard Therapy | recruiting | Phase 1 | 12 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT01089101 | Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma | active not recruiting | Phase 1 / Phase 2 | 217 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT03223103 | Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma | active not recruiting | Phase 1 | 13 | Adilia HormigoOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT03455270 | G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer | completed | Phase 1 | 107 | G1 Therapeutics, Inc.INDUSTRY | 7 | Sep 21, 2026 | clinicaltrials |
| NCT03588078 | Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine | completed | Phase 1 / Phase 2 | 53 | Groupe Francophone des MyelodysplasiesOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT03909412 | Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma(CarMob) | recruiting | Phase 1 | 18 | Hackensack Meridian HealthOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04216316 | Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04429087 | A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 | active not recruiting | Phase 1 | 306 | Boehringer IngelheimINDUSTRY | 4 | Sep 21, 2026 | clinicaltrials |
| NCT04464759 | A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma(LIMIT) | active not recruiting | Phase 1 / Phase 2 | 41 | Ravi Amaravadi, MDOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04601584 | GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL | terminated | Phase 1 / Phase 2 | 14 | AO GENERIUMINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04615845 | A Phase 1 Study of Autologous Dendritic Cell Immunotherapy in Patients With mCRPC | terminated | Phase 1 | 3 | Pharmicell Co., Ltd.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04644068 | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies(PETRA) | active not recruiting | Phase 1 / Phase 2 | 702 | AstraZenecaINDUSTRY | 14 | Sep 21, 2026 | clinicaltrials |
| NCT04827810 | A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer | suspended | Phase 1 | 42 | Fox Chase Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04977167 | Clinical Trial of HG146 Administered to Subjects With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 24 | HitGen Inc.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04977375 | Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma | recruiting | Phase 1 / Phase 2 | 10 | Chirag G. PatilOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05359211 | NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma | completed | Phase 1 | 27 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05521412 | EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T(VIOLET) | recruiting | Phase 1 / Phase 2 | 66 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05920798 | Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer(FRAPPE) | active not recruiting | Phase 1 / Phase 2 | 38 | Mayo ClinicOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05983432 | Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors | recruiting | Phase 1 | 540 | SystImmune Inc.INDUSTRY | 5 | Sep 21, 2026 | clinicaltrials |
| NCT06005740 | A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer | active not recruiting | Phase 1 | 70 | TORL Biotherapeutics, LLCINDUSTRY | 2 | Sep 21, 2026 | clinicaltrials |
| NCT06014086 | Intratumoral PH-762 for Cutaneous Carcinoma | completed | Phase 1 | 22 | Phio Pharmaceuticals Inc.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06021626 | A Study of CRD3874-SI in People With Solid Tumors | recruiting | Phase 1 | 81 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06029309 | Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma(ZANU-TAFA) | recruiting | Phase 1 / Phase 2 | 27 | Alvaro Alencar, MDOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06114511 | A Study of BL-M07D1 in Patients With HER2-Overexpressing or HER2-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 78 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06439836 | Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy | recruiting | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06529822 | Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease | recruiting | Phase 1 | 64 | Washington University School of MedicineOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06736379 | Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer | recruiting | Phase 1 | 41 | VLP TherapeuticsINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07162038 | Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation | recruiting | Phase 1 | 155 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07562841 | Au-TMP and Radiotherapy for Advanced Melanoma With Anti-PD-1 Therapy | recruiting | Phase 1 | 6 | West China HospitalOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07629960 | A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations | recruiting | Phase 1 / Phase 2 | 265 | Blueprint Medicines CorporationINDUSTRY | 2 | Sep 21, 2026 | clinicaltrials |
| NCT07645651 | Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer | recruiting | Phase 1 | 15 | University of WashingtonOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07692529 | A Clinical Study on the Efficacy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte Leukemia | not yet recruiting | Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Sep 21, 2026 | clinicaltrials |
| NCT07802717 | A Phase 1 Dose-escalation and Expansion Study of In Vivo BCMA-CAR T Cell Therapy (VV169) in Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 40 | Vyriad, Inc.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07831122 | Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE) | not yet recruiting | Phase 1 | 108 | Canadian Myeloma Research GroupOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07831187 | Entacapone Plus Bevacizumab for Glioblastoma at First Recurrence | not yet recruiting | Phase 1 / Phase 2 | 96 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT02530034 | Hu8F4 in Treating Patients With Advanced Hematologic Malignancies | active not recruiting | Phase 1 | 72 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT03214562 | Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 116 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT03587038 | OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma | active not recruiting | Phase 1 | 27 | University of OklahomaOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT03630991 | Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy | recruiting | Phase 1 | 58 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04021368 | RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome | terminated | Phase 1 | 51 | Ryvu Therapeutics SAINDUSTRY | 2 | Sep 18, 2026 | clinicaltrials |
| NCT04038619 | Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients | recruiting | Phase 1 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04614051 | A Phase 1 Study of Cellgram-DC in Patients With Advanced or Recurrent Epithelial Ovarian Cancer | terminated | Phase 1 | 2 | Pharmicell Co., Ltd.INDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 22, 2026source: clinicaltrials